Share on Facebook Share on Twitter Email
Answers.com

Innovative Medicines Initiative

 
Wikipedia: Innovative Medicines Initiative
Innovative Medicines Initiative
Joint Technology Initiative on Innovative Medicines
Keywords Drug discovery, Drug development
Funding agency European Commission

European Federation of Pharmaceutical Industries and Associations (EFPIA)

Project type Joint Technology Initiative (JTI)
Reference
Objective Re-invigorate the European bio-pharmaceutical sector and to make Europe more attractive for private research and development (R&D) investment in this sector
Participants
Budget Overall: 2 billion EUR

Funding: 1 billion EUR

Duration 2008 - 2017
Web site http://imi.europa.eu

The Innovative Medicines Initiative (IMI) is a European initiative to improve the competitive situation of the European Union in the field of pharmaceutical research. The IMI is a joint initiative (Public-Private Partnership) of the DG Research of the European Commission, representing the European Communities, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI is laid out as a Joint Technology Initiative within the Seventh Framework Programme.

The Innovative Medicines Initiative is aimed towards removing research bottlenecks in the current drug development process. The IMI Joint Technology Initiative (IMI JTI), to be implemented by the IMI Joint Undertaking is meant to address these research bottlenecks.

The Sixth Framework Programme's research projects InnoMed AddNeuroMed and InnoMed PredTox act as pilot projects establishing the feasibility of this particular public-private partnership[1].

See also


References

  1. ^ Reference on EFPIA's IMI site [1]

External links


Search unanswered questions...
Enter a question here...
Search: All sources Community Q&A Reference topics
 
 

 

Copyrights:

Wikipedia. This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article "Innovative Medicines Initiative" Read more